This study demonstrates that treatment of RA patients with agents that have different mechanisms of action, either T cell modulation or TNF inhibition, will lead to comparable clinical benefit, suggesting that these 2 agents should be considered equally for the treatment of RA patients who have an inadequate response to MTX. This evidence concerns the gene TNF and rheumatoid arthritis.